The Cirio life science team regularly advises big pharma as well as small and midsize pharma companies in areas such as clinical trials, manufacturing, pricing and reimbursement, marketing and interactions with healthcare professionals and public procurement/government contracts. Our team has also developed significant experience in ATMP’s and value-based pricing models.

Following the inclusion of Odd Swarting (formerly Calissendorff & Swarting) in 2020 and Hanna Tilus (formerly Roschier and Bayer) in 2021, Cirio has one of the strongest and most experienced life science teams in Sweden, covering all the key areas for pharma companies active on, or seeking to enter the Swedish market.

Just like the other sector groups, the life science team has a strong transactional focus and has advised on some of the most substantial pharma related transactions in Sweden in recent years, regarding licensing/partnering, M&A and take-overs.

In the IT and data fields, our team offers multi-disciplinary capabilities. In this context the team has been involved in large and complex cases relating to collaborations with digital service providers (e.g., apps), cloud computing and outsourcing of patient data.

Relaterad expertise

Related news